T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced on March 28, 2024, the extension of its multi-year capital equipment supplier agreement with Vizient, Inc. through March 31, 2025. The agreement allows Vizient members continued access to T2 Biosystems' products, including the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel, which are the only FDA-cleared products for direct detection of sepsis-causing pathogens from blood. Vizient, Inc. is the largest member-driven health care performance improvement company in the U.S., representing a significant portion of the nation's health care organizations. The extension of this contract underscores the value of T2 Biosystems' technology in the health care market and its potential to improve patient outcomes by enabling faster targeted therapy for sepsis.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced on March 28, 2024, the extension of its multi-year capital equipment supplier agreement with Vizient, Inc. through March 31, 2025. The agreement allows Vizient members continued access to T2 Biosystems' products, including the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel, which are the only FDA-cleared products for direct detection of sepsis-causing pathogens from blood. Vizient, Inc. is the largest member-driven health care performance improvement company in the U.S., representing a significant portion of the nation's health care organizations. The extension of this contract underscores the value of T2 Biosystems' technology in the health care market and its potential to improve patient outcomes by enabling faster targeted therapy for sepsis.